IL2-receptor antagonist (basiliximab) induction therapy is associated with lower morbidity and mortality in renal transplant recipients.

Article Details

Citation

Copy to clipboard

Choy BY, Chan TM, Li FK, Lui SL, Lo WK, Yip T, Tse KC, Lai KN

IL2-receptor antagonist (basiliximab) induction therapy is associated with lower morbidity and mortality in renal transplant recipients.

Transplant Proc. 2003 Feb;35(1):195.

PubMed ID

12591363 [ View in PubMed

]

Abstract

Not Available

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Basiliximab	Interleukin-2 receptor subunit alpha	Protein	Humans	Yes	Antibody	Details